Published On: Tue, Sep 13th, 2016

NeuroMetrix Inc. (NURO) Upgraded to “Hold” by Zacks Investment Research

NeuroMetrix Inc. (NASDAQ:NURO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday.
According to Zacks, “Neurometrix is a medical device company establishing a new standard of care through the design, development and sale of proprietary products used to diagnose neuropathies. Neuropathies are diseases of the peripheral nerves and parts of the spine that frequently are caused by or associated with diabetes, low back pain and carpal tunnel syndrome, as well as other clinical disorders. “
Separately, Rodman & Renshaw restated a “buy” rating on shares of NeuroMetrix in a research report on Friday, July 22nd.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

NeuroMetrix (NASDAQ:NURO) opened at 1.39 on Tuesday. The firm’s market cap is $7.11 million. NeuroMetrix has a 12 month low of $1.35 and a 12 month high of $3.80. The company’s 50-day moving average is $1.50 and its 200 day moving average is $1.68.
NeuroMetrix (NASDAQ:NURO) last posted its quarterly earnings results on Thursday, July 21st. The medical device company reported ($5.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by $4.44. NeuroMetrix had a negative net margin of 145.17% and a negative return on equity of 136.95%. The business earned $2.65 million during the quarter, compared to the consensus estimate of $1.22 million. Equities research analysts expect that NeuroMetrix will post ($6.65) EPS for the current fiscal year.
An institutional investor recently raised its position in NeuroMetrix stock. Renaissance Technologies LLC increased its position in NeuroMetrix Inc. (NASDAQ:NURO) by 57.2% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 57,700 shares of the medical device company’s stock after buying an additional 21,000 shares during the period. Renaissance Technologies LLC owned 1.43% of NeuroMetrix worth $106,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.62% of the company’s stock.
NeuroMetrix Company Profile
NeuroMetrix, Inc (NeuroMetrix) is a health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians manage chronic pain, nerve diseases and sleep disorders. The Company operates through the sale of medical equipment and consumables segment. Its products are sold in the United States and selected overseas markets.

Receive News & Ratings for NeuroMetrix Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeuroMetrix Inc. and related companies with’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>